Mechanism of action of beta-blocking agents in heart failure

American Journal of Cardiology

Volumn 80, Issue 11 A, 1997, Pages

  Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUCINDOLOL; CARVEDILOL; METOPROLOL; PROPRANOLOL; TIMOLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CONFERENCE PAPER; DRUG EFFECT; DRUG RECEPTOR BINDING; HEART FAILURE; HEART INNERVATION; HEART LEFT VENTRICLE FUNCTION; HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0030660245     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00846-1     Document Type: Conference Paper

References (150)

1. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Johnson M, Silver MA, Gilbert EM, Hjalmarson Å. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
2. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker M, Marshall G, Kelly P, Deitchman D, Anderson JL. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation. 89:1994;1632-1642.
3. A randomized trial of beta-blockade in heart failure The Cardiac Insufficiency Bisoprolol Study (CIBIS) . Circulation. 90:1994;1765-1773.
4. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.
5. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 94:1996;2807-2816.
6. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger S, Hershberger RE, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 94:1996;2800-2806.
7. Bristow MR, Ginsburg R, Minobe WA, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med. 307:1982;205-211.
8. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. β-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 17:(suppl 2):1985;41-52.
9. Fowler MB, Bristow MR. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol. 55:1985;D120-D124.
10. Bristow MR. The adrenergic nervous system in heart failure. N Engl J Med. 311:1984;850-851.
11. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 71:1993;12C-22C.
12. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biologic effects of medical therapy a new concept in the treatment of heart failure . Eur Heart J. 16:(suppl F):1995;20-31.
13. Eichhorn EJ, Bristow MR. Medical therapy can improve the biologic properties of the chronically failing heart a new era in the treatment of heart failure . Circulation. 94:1996;2285-2296.
14. 1 receptor downregulation in heart failure . Circ Res. 59:1986;297-309.
15. 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy . J Cardiovasc Pharmacol. 8:1986;1235-1242.
16. Bohm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold J, Erdmann E. Subsensitivity of the failing human heart to isoproterenol and milrinone is related to β-adrenoceptor downregulation. J Cardiovasc Pharmacol. 12:1988;726-732.
17. Bristow MR, Anderson FL, Port JD, Skerl L, Hershberger RE, Larrabee P, O'Connell JB, Renlund DG, Volkman K, Murray J, Feldman AM. Differences in β-adrenergic neuroeffector mechanisms in ischemic vs idiopathic dilated cardiomyopathy. Circulation. 84:1991;1024-1039.
18. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV, Fowler M, Ginsburg R. β-adrenergic neuroeffector abnormalities in the failing human heart are produced by local, rather than systemic mechanisms. J Clin Invest. 89:1992;803-815.
19. 1 receptor mRNA abundance in the failing human heart. J Clin Invest. 92:1993;2737-2745.
20. 1-adrenergic receptors in the failing human heart. Circulation. 87:1993;454-463.
21. Brodde O-E. Beta-adrenoceptors in cardiac disease. Pharmacol Rev. 60:1993;405-430.
22. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the β-adrenergic receptor pathway in the intact failing human heart progressive receptor down-regulation and subsensitivity to agonist response . Circulation. 74:1986;1290-1302.
23. Colucci WS, Denniss AR, Leatherman GF, Quigg RJ, Ludmer PL, Marsh JD, Gauthier DF. Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. J Clin Invest. 81:1988;1103-1110.
24. Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 79:1989;483-490.
25. Glass MG, Fueihan F, Liao R, Lincoff AM, Chapados R, Hamlin R, Apstein CS, Allen PD, Ingwall JS, Hajjar R, Cory CR, O'Brien PJ, Gwathmey JK. Differences in cardioprotective efficacy of adrenergic receptor antagonists in an animal model of dilated cardiomyopathy effects on gross morphology, global cardiac function, and twitch force . Circ Res. 73:1993;1077-1089.
26. Tsutsui H, Spinale FG, Nagatsu M, Schmid PG, Ishihara K, DeFreyte G, Cooper G, Carabello BA. Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest. 93:1994;2639-2648.
27. Mann DL, Kent RL, Parsons B, Cooper G IV. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 85:1992;790-804.
28. Harding SE, Jones SM, del Monte F, Vescovo G, Poole-Wilson PA. Isolated ventricular myocytes from failing and nonfailing human heart the relation of age and clinical status to isoproterenol response . J Mol Cell Cardiol. 24:1992;549-564.
29. 2-adrenergic receptor. Science. 264:1994;562-566.
30. 1-adrenergic receptor gene developmental and cardiovascular effects . Proc Natl Acad Sci USA. 93:1996;7375-7380.
31. 1-adrenergic receptor. (Abstr.). J Invest Med. 45:1997;210A.
32. Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP, Kudej RK, Wight DC, Wagner TE, Ishikawa Y, Homcy CJ, Vatner SF. Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsα overexpression. Circ Res. 78:1996;517-524.
33. Esler M, Kaye D, Lambert G, Esler D, Jennings G. Adrenergic Nervous System in Heart Failure. Am J Cardiol. 80:(suppl):1997;7L-14L.
34. Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, Chaterjee K. Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without heart failure. Am J Cardiol. 54:1984;783-786.
35. Hasking GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with chronic congestive heart failure Evidence of increased overall and cardiorenal sympathetic nervous activity . Circulation. 73:1986;615-621.
36. Kaye DM, Lefkovits J, Jennings GL, Bergin P, Broughton A, Esler D. Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol. 26:1995;1257-1263.
37. Rundquist B, Elam M, Bermann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 95:1997;169-175.
38. Ginsburg R, Esserman LJ, Bristow MR. Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med. 98:1983;603-606.
39. White M, Yanowitz F, Gilbert EM, Larrabee P, O'Connell JB, Anderson JL, Renlund D, Mealey P, Abraham WT, Bristow MR. Role of beta-adrenergic receptor downregulation in the peak exercise response of patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol. 76:1995;1271-1276.
40. Reithmann C, Gierschik P, Sidiropoulos D, Werdan K, Jakobs KH. Mechanism of noradrenaline-induced heterologous desensitization of adenylate cyclase stimulation in rat heart muscle cells increase in the level of inhibitory G-protein α-subunits . Eur J Pharmacol. 172:1989;211-221.
41. Bristow MR, Durham C, Kline J, Rasmussen R, Port JD, Gesteland RR, Barry WH, Feldman AM. Downregulation of β-adrenergic receptors and receptor mRNA in heart cells chronically exposed to norepinephrine. (Abstr.). Clin Res. 39:1991;256A.
42. Gilbert EM, Sandoval A, Larrabee P, Renlund DG, O'Connell JB, Bristow MR. Lisinopril lowers cardiac adrenergic drive and increases β-receptor density in the failing human heart. Circulation. 88:1993;472-480.
43. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson Å. Long-term β-blockade in dilated cardiomyopathy. Circulation. 80:1989;551-563.
44. 2-adrenoceptors in human atrial myocardium. Circ Res. 66:1990;1610-1623.
45. White M, Wiechmann RJ, Roden RL, Hagan MB, Wollmering MM, Port JD, Hammond E, Abraham WT, Wolfel EE, Lindenfeld J, Fullerton D, Bristow MR. Cardiac β-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury evidence for catecholamine-mediated myocardial damage . Circulation. 92:1995;2183-2189.
46. Imperato-McGinley J, Gautier T, Ehlers K, Zullo MA, Goldstein DS, Vaughan ED Jr. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma. N Engl J Med. 316:1987;793-797.
47. Cintron C, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. Circulation. 87:(suppl VI):1993;VI-17-VI-23.
48. Haber HL, Christopher LS, Gimple LW, Bergin JD, Subbiah ME, Jayaweera AR, Powers ER, Feldman MD. Why do patients with congestive heart failure tolerate the initiation of β-blocker therapy? Circulation. 88:1993;1610-1619.
49. Lowes BD, Minobe WA, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Bristow MR. Changes in gene expression in the intact human heart: downregulation of α-myosin heavy chain in hypertrophied failing ventricular myocardium. J Clin Invest 1997: in press.
50. Bristow MR, Gilbert EM, Lowes BD, Minobe W, Shakar J, Quaife RA, Abraham WT. Changes in myocardial gene expression associated with β-blocker related improvement in ventricular systolic function. Circulation 1997: in press.
51. Arai M, Matsui H, Periasamy M. Sarcoplasmic reticulum gene expression in cardiac hypertrophy and heart failure. Circ Res. 74:1994;555-564.
52. Brillantes A-M, Allen P, Takahashi T, Izumo S, Marks AR. Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemic versus dilated cardiomyopathy. Circ Res. 71:1992;18-26.
53. Katz A. Cellular mechanisms in congestive heart failure. Am J Cardiol. 62:1988;3A-8A.
54. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy a randomized, double-blind, placebo-controlled study . J Am Coll Cardiol. 24:1994;1310-1320.
55. Laragh JH, Angers M, Kelly WG, Lieberman S. Hypotensive agents and pressor substances the effect of epinephrine, norepinephrine, angiotensin II, and others on the secretory rate of aldosterone in man . JAMA. 174:1960;234-240.
56. Bristow MR, Abraham WT. Anti-adrenergic effects of angiotensin converting enzyme inhibitors. Eur Heart J. 16:1995;37-41.
57. White M, Roden R, Minobe W, Khan MF, Larrabee P, Wollmering M, Port JD, Anderson F, Campbell D, Feldman AM, Bristow MR. Age-related changes in β-adrenergic neuroeffector systems in the human heart. Circulation. 90:1994;1225-1238.
58. 2 adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol. 35:1989;295-303.
59. 3-adrenoceptor in the human heart. J Clin Invest. 98:1996;556-562.
60. Bristow MR, Sherrod TR, Green RD. Analysis of beta receptor drug interactions in isolated rabbit atrium, aorta, stomach and trachea. J Pharmacol Exp Ther. 171:1970;52-61.
61. 3-adrenergic receptor. Science. 245:1989;1118-1121.
62. Bohm M, Diet F, Feiler G, Kemkes B, Erdmann E. α-Adrenoceptors and α-adrenoceptor-medicated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol. 12:1988;357-364.
63. 1-adrenergic receptor stimulation and blockade on contractility in humans. Circulation. 84:1991;1608-1614.
64. Moravec CS, Schluchter MD, Paranandi L, Czerska B, Stewart RW, Rosenkranz E, Bond M. Inotropic effects of angiotensin II on human cardiac muscle in vitro. Circulation. 82:1990;1973-1984.
65. Holubarsch C, Hasenfuss G, Schmidt-Schweda S, Knorr A, Pieske B, Ruf T, Fasol R, Just H. Angiotensin I and II exert inotropic effects in atrial but not in ventricular human myocardium an in vitro study under physiological experimental conditions . Circulation. 88:1993;1228-1237.
66. 1A cells. J Biol Chem. 270:1995;19059-19065.
67. 2-adrenoceptors, are innervated. J Pharm Pharmacol. 34:1982;664-666.
68. Iversen LL. Uptake processes for biogenic amines. Handbook of Psychopharmacology. 3:1975;381-442.
69. Abraham WT, Lowes BD, Rose CP, Larrabee P, Bristow MR. Angiotensin II selectively increases cardiac adrenergic activity in patients with heart failure. (Abstr.). J Am Coll Cardiol. February:1994;215A.
70. Pende A, Mitchusson KD, DeMaria CT, Blaxall BC, Minobe WA, Sherman JS, Bristow MR, Brewer G, Port JD. Regulation of the mRNA-binding protein AUF1 by activation of the β-adrenergic receptor signal transduction pathway. J Biol Chem. 271:1996;8493-8501.
71. Bristow MR. Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol. 22:(suppl A):1993;61A-71A.
72. Kaye DM, Cox H, Lambert G, Jennings GL, Turner A, Esler MD. Regional epinephrine kinetics in severe heart failure evidence for extra-adrenal, nonneural release . Am J Physiol. 269:1995;H182-H188.
73. Ungerer M, Parruti G, Bohm M, Puzicha M, DeBlasi A, Erdmann E, Lohse MJ. Expression of β-arrestins and β-adrenergic receptor kinases in the failing human heart. Circ Res. 74:1994;206-213.
74. 1-adrenergic receptor. J Biol Chem. 270:1995;17953-17961.
75. Roth NS, Campbell PT, Caron MG, Lefkowitz RJ, Lohse MJ. Comparative rates of desensitization of β-adrenergic receptors by the β-adrenergic receptor kinase and the cyclic AMP-dependent protein kinase. Proc Natl Acad Sci USA. 88:1991;6201-6204.
76. 2 subunits of heterotrimeric G proteins on the β-adrenergic receptor kinase. J Biol Chem. 268:1993;8256-8260.
77. Bohm M, Reiger B, Swinger RHG, Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in nonfailing and failing myocardium. Cardiovasc Res. 28:1994;1713-1719.
78. r 40,000 pertussis toxin substrate (G protein) in the failing human heart. J Clin Invest. 82:1988;189-197.
79. Feldman AM, Jackson DG, Bristow MR, Cates AE, Van Dop C. Immunodetectable levels of the inhibitory guanine nucleotide binding proteins in failing human heart discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate . J Mol Cell Cardiol. 23:1991;439-452.
80. i proteins in heart failure. Lancet. 2:1988;936-937.
81. Böhm M, Eschenhagen T, Gierschik P, Larisch K, Lensche H, Mende U, Schmitz W, Schnabel P, Scholz H, Steinfath M, Erdmann E. Radioimmunochemical quantification of GIα in right and left ventricles from patients with ischemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol. 26:1994;133-149.
82. Feldman MF, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W, Morgan JP. Deficient production of cAMP pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure . Circulation. 75:1987;331-339.
83. Danielsen W, van der Leyen H, Meyer W, Neumann J, Schmitz W, Scholtz H, Starbatty J, Doring V, Kalmar P. Basal and Isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol. 14:1989;171-173.
84. Meuse AJ, Perreault CL, Morgan JP. Pathophysiology of cardiac hypertrophy and failure of working myocardium abnormalities in calcium handling . Basic Res Cardiol. 87:(suppl 1):1992;223-233.
85. s and adenylyl cyclase activities in compensated left ventricular hypertrophy in heart failure, only the impairment in adenylyl cyclase activation progresses . J Clin Invest. 87:1991;293-298.
86. 2-adrenergic stimulation in man using atenolol and propranolol. Circulation. 67:1983;1076-1084.
87. 1receptor subtype in failing human ventricular myocardium. Circulation. 95:1997;1193-2000.
88. Colucci WS, Ribeiro JP, Rocco MB, Quigg RJ, Creager MA, Marsh JD, Gauthier DF, Hartley LH. Impaired chronotropic response to exercise in patients with congestive heart failure. Circulation. 80:1989;314-323.
89. Wollmering MM, Wiechmann RJ, Port JD, Hershberger RE, Focaccio A, Bristow MR. Dobutamine is a partial agonist with an intrinsic activity of 0.5 in human myocardium. (Abstr.). J Am Coll Cardiol. 17:1991;283A.
90. Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol. 80:(suppl):1997;15L-25L.
91. Davies CH, Davia K, Bennett JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation. 92:1995;2540-2549.
92. Schwinger RHG, Bohm M, Koch A, Schmidt U, Morano I, Eissner H-J, Uberfuhr P, Reichart B, Erdmann E. The failing human heart is unable to use the Frank-Starling mechanism. Circ Res. 74:1994;959-969.
93. Holubarsch C, Thorsten R, Goldstein DJ, Ashton RC, Nickl BS, Pieske B, Pioch K, Ludemann J, Wiesner S, Hasenfuss G, Posival H, Just H, Burkhoff D. Existence of the Frank-Starling mechanism in the failing human heart investigations on the organ, tissue, and sarcomere levels . Circulation. 94:1996;683-689.
94. Mercadier JJ, Lompre AM, Duc P, Boheler KR, Fraysse JB, Wisnewsky C, Allen PD, Komajda M, Schwartz K. Altered sarcoplasmic reticulum Ca-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 85:1990;305-309.
95. 2+ ATPase in failing and nonfailing human myocardium. Circ Res. 75:1994;434-442.
96. Swynghedauw B. Developmental and functional adaptation of contractile proteins in cardiac and skeletal muscles. Physiol Rev. 66:1986;710-730.
97. Schwartz K, Chassagne C, Boheler KR. The molecular biology of heart failure. J Am Coll Cardiol. 22:(suppl A):1993;30A-33A.
98. Raynolds MV, Bush EW, Taft CS, Roden RA, Bristow MR. Altered gene expression of several rate limiting enzymes in fatty acid oxidation and glycolysis in the failing human heart. (Abstr.). Circulation. 90:1994;I-209.
99. Nascimben L, Ingwall JS, Pauletto P, Friedrich J, Gwathmey JK, Saks V, Pessina AC, Allen PD. Creatine kinase system in failing and nonfailing human myocardium. Circulation. 94:1996;1894-1901.
100. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease altered cardiac high-energy phosphate metabolism in heart failure . Circulation. 86:1992;1810-1818.
101. Tsutsui H, Ishihara K, Cooper G IV. Cytoskeletal role in the contractile dysfunction of hypertrophied myocardium. Science. 260:1993;682-687.
102. Maeda M, Holder E, Lowes B, Valent S, Bies RD. Dilated cardiomyopathy associated with deficiency of the cytoskeletal protein metavinculin. Circulation. 95:1997;17-20.
103. Melacini P, Fanin M, Danieli GA, Villanova C, Martinello F, Miorin M, Freda MP, Miorelli M, Mostacciuolo ML, Fasoli G, Angelini C, Dalla Volta S. Myocardial involvement is very frequent among patients affected with subclinical Becker's Muscular Dystrophy. Circulation. 94:1996;3168-3175.
104. Ziegler K. Uber die Wirkung intravenöser Adrenalin-injektion auf das Gefäfssytem und ihre Beziehung zur Arteriosklerose. Bietr Pathologischen Anatonie. 38:1905;229-254.
105. Fleckenstein A. Specific inhibitor and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie LH, eds. Calcium and the Heart. London: Academic Press, 1971:135-188.
106. 1-selective blockade. Lancet. 12:1987;585-589.
107. Haft JI. Cardiovascular injury induced by sympathetic catecholamines. Prog Cardiovasc Dis. 17:1974;73-85.
108. Tan LB, Benjamin IJ, Clark WA. β Adrenergic receptor desensitisation may serve a cardioprotective role. Cardiovasc Res. 26:1992;608-614.
109. Searle J, Kerr JF, Bishop CJ. Necrosis and apoptosis distinct modes of cell death with fundamentally different significance . Pathol Annu. 17:1982;229-259.
110. Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M. Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes. Circ Res. 75:1994;426-433.
111. Kaistura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest. 74:1996;86-107.
112. Teiger E, Dam TV, Richard L, Wisnewsky C, Tea BS, Gaboury L, Tremblay J, Schwartz K, Hamet P. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest. 97:1996;2891-2897.
113. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 335:1996;1182-1189.
114. Geng YJ, Ishikawa Y, Vatner DE, Wagner TE, Bishop SP, Vatner SF, Homcy CJ. Overexpression of Gsα accelerates programmed death (apoptosis) of myocardiocytes in transgenic mice. (Abstr.). Circulation Suppl. 94:1996;1640.
115. Erlebacher JA, Weiss JL, Eaton L, Kallman C, Weisfeldt ML, Bulkley BH. Late effects of acute infarct dilation on heart size a two dimensional echocardiographic study . Am J Cardiol. 48:1982;1120-1126.
116. Sabbah HN, Goldstein S. Ventricular remodeling consequences and therapy . Eur Heart J. 14:(suppl C):1993;24-29.
117. Cohn JN. Structural basis for heart failure Ventricular remodeling and its pharmacological inhibition . Circulation. 91:1995;2504-2507.
118. Gerdes AM, Kellerman SE, Moore JA, Clark LC, Reaves PY, Malec KB, Muffly KE, McKeown PP, Schocken DD. Structural remodeling of cardiac myocytes from patients with chronic ischemic heart disease. Circulation. 86:1992;426-430.
119. Gerdes AM, Kellerman SE, Schocken DD. Implications of cardiomyocyte remodeling in heart dysfunction. In: Dhalla NS, Beamish RE, Takeda N, Nagano N, eds. The Failing Heart. New York: Raven Press, 1995:197-205.
120. Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 56:1975;56-64.
121. Wollert KC, Taga T, Saito M, Narazaki M, Kishimoto R, Clembotski CG, Vernallis AB, Heath JK, Pennica D, Woods WI, Chien KR. Cardiotrophin-1 activates a distinct form of cardiac muscle cell hypertrophy. J Biol Chem. 271:1996;9535-9545.
122. Chidiac P, Herbert TE, Valiquette M, Dennis M, Bouvier M. Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol. 45:1993;490-499.
123. 2-adrenergic receptor. Mol Pharmacol. 45:1993;390-394.
124. 2-adrenoceptor. Nature. 374:1995;272-276.
125. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, LV functional, and antiadrenergic effects of chronic treatment with metoprolol vs carvedilol in the failing heart. Circulation. 94:1996;2817-2825.
126. Lowes BD, Abraham WT, Dutcher DL, Roden RL, Crisman TS, Minobe W, Port JD, Larrabee P, Gilbert EM, Bristow MR. Comparative antiadrenergic effects of carvedilol and metoprolol in a randomized, placebo-controlled trial. (Abstr.). Circulation Suppl. 94:1996;I-664.
127. Metra M, Nardi M, Giubbini R, Dei Cas L. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 24:1994;1678-1687.
128. Olsen SL, Gilbert EM, Renlund DG, Mealey PC, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in heart failure a double-blind randomized study . J Am Coll Cardiol. 25:1995;1225-1231.
129. Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 92:1995;1499-1506.
130. Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol. 78:1996;779-784.
131. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation. 92:1995;212-218.
132. Lowes BD, Gill EA, Rodriguez-Larrain J, Abraham WT, Bristow MR, Gilbert EM. Carvedilol is associated with a reversal of remodeling in chronic heart failure. (Abstr.). Circulation. 94:(suppl 1):1996;I-407.
133. Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol. 25:1995;1154-1161.
134. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP. Beneficial effects of metoprolol in heart failure associated with coronary artery disease a randomized trial . J Am Coll Cardiol. 23:1994;943-950.
135. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy a double-blind, randomized, placebo-controlled trial . Circulation. 72:1985;536-546.
136. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction Results of the SOLVD Echocardiograpy Substudy . Circulation. 91:1995;2573-2581.
137. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 37:1975;1022-1036.
138. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Chronic β-blocker-vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy a double-blind, randomized study of bucindolol versus placebo . Am J Med. 88:1990;223-229.
139. Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML. Usefulness of bucindolol in congestive heart failure. Am J Cardiol. 66:1990;603-607.
140. Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield B, Deitchman D, Brown M, Willard JE, Grayburn PA. Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure improvements in hemodynamic, contractile, and diastolic performance with bucindolol . Circulation. 82:1990;473-483.
141. Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P. Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol. 21:1993;1094-1100.
142. Sen S, Tarazi RC. Regression of myocardial hypertrophy and influence of the adrenergic system. Am J Physiol. 244:1983;H97-H101.
143. Packer M. Effect of beta-adrenergic blockade on the survival of patients with chronic heart failure concepts, conclusions, and controversies . Am J Cardiol. 80:(suppl):1997;46L-54L.
144. Design of the Beta-Blocker Evaluation Survival Trial (BEST). Am J Cardiol. 75:1995;1220-1223.
145. Lowes BD, Chidiac P, Olsen S, Port JD, Bouvier M, Gilbert EM, Bristow MR. Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of β-adrenergic receptor blocking agents. (Abstr.). Circulation. 90:1994;I-543.
146. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Trammel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 17:(suppl B):1996;8-16.
147. Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Larrabee P, Gilbert EM. Second- and third-generation β-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther. 11:1997;291-296.
148. Chadda K, Goldstein S, Byington R, Curb JD. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation. 73:1986;503-510.
149. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 304:1981;801-807.
150. Eichhorn EE, Bristow MR. Practical guidelines for initiation of β-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 79:1997;794-798.